This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Grupo Financiero Galicia Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Grupo Financiero Galicia.
Grupo Financiero Galicia Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Grupo Financiero Galicia.
Implied Volatility Surging for Grupo Financiero Galicia (GGAL) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Grupo Financiero Galicia (GGAL) stock based on the movements in the options market lately.
What Makes Grupo Financiero Galicia (GGAL) a Strong Sell?
by Zacks Equity Research
Grupo Financiero Galicia (GGAL) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Grupo Financiero Galicia (GGAL) Surges: Stock Moves 7.6% Higher
by Zacks Equity Research
Grupo Financiero Galicia (GGAL) was a big mover last session, as the company saw its shares rise more than 7% on the day amid huge volumes.
Should You Buy Grupo Financiero Galicia (GGAL) Ahead of Earnings?
by Zacks Equity Research
Grupo Financiero Galicia (GGAL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Zacks.com highlights: Amtech Systems, Grupo Financiero Galicia S.A., Calithera Biosciences, RedHill Biopharma and Protagonist Therapeutics
by Zacks Equity Research
Zacks.com highlights: Amtech Systems, Grupo Financiero Galicia S.A., Calithera Biosciences, RedHill Biopharma and Protagonist Therapeutics
5 Stocks in Focus on New Analyst Coverage
by Zacks Equity Research
Increased analyst coverage over the last few weeks might translate into solid price appreciation for these stocks.
Zacks.com featured highlights include article Kraton, aTyr Pharma, Grupo Financiero Galicia, Grupo Supervielle and Calithera Biosciences
by Zacks Equity Research
Zacks.com featured highlights include article Kraton, aTyr Pharma, Grupo Financiero Galicia, Grupo Supervielle and Calithera Biosciences
5 Stocks to Add to Your Portfolio on New Analyst Coverage
by Zacks Equity Research
Increased analyst coverage over the last few weeks might translate into solid price appreciation for these stocks.
Zacks.com featured highlights: BayerischeMotorenWerke, Gray Television, Grupo Financiero Galicia and Spark New Zealand
by Zacks Equity Research
Zacks.com featured highlights: BayerischeMotorenWerke, Gray Television, Grupo Financiero Galicia and Spark New Zealand
Forget Profit, Bet on 4 Stocks With Increasing Cash Flows
by Zacks Equity Research
Cash offers vitality and strength and is indeed the key to a company's existence, development and success.
Zacks.com featured highlights: Bayer AG, OMV AG, Grupo Financiero Galicia S.A. and Spark New Zealand
by Zacks Equity Research
Zacks.com featured highlights: Bayer AG, OMV AG, Grupo Financiero Galicia S.A. and Spark New Zealand
Buy 4 Stocks With Increasing Cash Flows Ahead of Q2 Earnings
by Zacks Equity Research
Cash gives a company the flexibility to make decisions, the means to make potential investments and the fuel to run its growth engine.
UBS to Fuse European & Emerging Markets Wealth Management
by Zacks Equity Research
Amid a challenging revenue environment, restructuring continues to be the core agenda for most global banks. In a latest move, Swiss banking giant, UBS Group AG (UBS), plans to merge its European and emerging markets wealth-management business.
Deutsche Bank (DB) Streamlines Units, Aims Cost Savings
by Zacks Equity Research
Per a Bloomberg report, Frankfurt-based German lender ??? Deutsche Bank AG (DB) ??? plans restructuring of its Corporate & Investment Banking (CIB) business segment, along with formation of a new unit ??? Global Capital Markets.
Deutsche Bank (DB) Nearing EURIBOR Settlement for Over $170M
by Zacks Equity Research
Legal hassles for major global banks continue unabated. The German lender ??? Deutsche Bank AG (DB) ??? has agreed to settle investors' lawsuit by paying $170 million.
Banco Santander (SAN) Wins Auction to Acquire Banco Popular
by Zacks Equity Research
Banco Santander, S.A. (SAN) announced on Wednesday that it has succeeded in the auction conducted by the Single Resolution Board, the new European authority dealing with failing banks, to acquire Banco Popular.
Will Barclays Divest Further Stake in Africa Unit Soon?
by Zacks Equity Research
Barclays (BCS) is awaiting regulatory approvals to further divest its stake in Barclays Africa Group. This news was first reported by Bloomberg last week.
Foreign Banks Stock Outlook - May 2017
by Kalyan Nandy
With the International Monetary Fund (IMF) raising its global economic growth outlook last month and buoyancy in the U.S. and emerging markets, foreign banks' prospects for the upcoming quarters are even better.
Mitsubishi UFJ (MTU) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Mitsubishi UFJ Financial Group, Inc. (MTU) is scheduled to report fourth-quarter and fiscal 2017 (ended Mar 31) results on May 15.
by Zacks Equity Research
5 Stocks with Recent Price Strength to Boost Your Portfolio
by Zacks Equity Research
One should primarily look for stocks that have witnessed price increases lately. Actually, such stocks have a high chance of carrying the momentum forward.
5 Solid Relative Price Strength Stocks to Make You Rich
by Nilanjan Choudhury
We ran a screen to select 5 stocks with solid relative price strength you want to have.
9 Stocks with Recent Price Strength for Extraordinary Returns
by Zacks Equity Research
One should primarily look for stocks that have recently been witnessing price increase. Actually, stocks seeing price strength recently have a high chance of carrying the momentum forward.